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Abstract
Preeclampsia is a pregnancy-specific hypertensive syndrome that causes substantial maternal and
fetal morbidity and mortality. Recent evidence indicates that maternal endothelial dysfunction in
preeclampsia results from increased soluble Fms-like tyrosine kinase-1 (sFlt-1), a circulating
antiangiogenic protein. Factors responsible for excessive production of sFlt-1 in preeclampsia
have not been identified. We tested the hypothesis that angiotensin II type 1 (AT1) receptor
activating autoantibodies, which occur in women with preeclampsia, contribute to increased
production of sFlt-1. IgG from women with preeclampsia stimulates the synthesis and secretion of
sFlt-1 via AT1 receptor activation in pregnant mice, human placental villous explants, and human
trophoblast cells. Using FK506 or short-interfering RNA targeted to the calcineurin catalytic
subunit mRNA, we determined that calcineurin/nuclear factor of activated T-cells signaling
functions downstream of the AT1 receptor to induce sFlt-1 synthesis and secretion by AT1-
receptor activating autoantibodies. AT1-receptor activating autoantibody–induced sFlt-1 secretion
resulted in inhibition of endothelial cell migration and capillary tube formation in vitro. Overall,
our studies demonstrate that an autoantibody from women with preeclampsia induces sFlt-1
production via angiotensin receptor activation and downstream calcineurin/nuclear factor of
activated T-cells signaling. These autoantibodies represent potentially important targets for
diagnosis and therapeutic intervention.
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Preeclampsia is a pregnancy-specific syndrome of hypertension and proteinuria, resulting in
substantial maternal and neonatal morbidity and mortality.1 Although the underlying
pathogenic mechanisms of the disorder are not well understood, preeclampsia is largely
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believed to be associated with uteroplacental ischemia and maternal endothelial cell
dysfunction.2–5 It is a widely held view that “toxic factors” secreted by the placenta into the
maternal circulation are responsible for systemic endothelial dysfunction, hypertension, and
multiorgan damage.6–11 Recent research has shown that soluble Fms-like tyrosine kinase-1
(sFlt-1) is 1 of the key “toxic factors” released by the placenta into the maternal circulation
and that it contributes to the hypertension, proteinuria, and endothelial cell dysfunction
associated with this disorder.12–15 sFlt-1 is a soluble form of the vascular endothelial growth
factor receptor that lacks the cytoplasmic tail and transmembrane domain but retains the
extracellular ligand-binding domain (sFlt-1 is also named sVEGFR1). Therefore, sFlt-1
prevents circulating vascular endothelial growth factor and placental growth factor
interactions with their proangiogenic receptors and functions as an antiangiogenic factor.
The level of sFlt-1 in the plasma of women with preeclampsia is elevated in comparison
with that in women with uncomplicated pregnancies,16–18 a feature consistent with
microarray data showing that sFlt-1 mRNA levels are elevated in placentas from women
with preeclampsia compared with placentas of normotensive pregnant women.12 The
physiological consequences of elevated sFlt-1 in preeclampsia have been examined recently
in animal studies. Administration of sFlt-1 to rats resulted in elevated blood pressure,
proteinuria, and renal changes, indicating that excessive placental-derived sFlt-1 may
contribute to these classic features preeclampsia. In view of the critical contributions of
sFlt1 to disease pathogenesis, it is important to identify factors responsible for increased
synthesis and secretion of sFlt-1 by the placentas of women with preeclampsia.
A local renin-angiotensin system plays an important role in regulating placental
development.19–24 Decidual tissue is enriched in the components needed for angiotensin II
(Ang II) production (ie, renin, angiotensinogen, and angiotensin-converting enzyme), and
placental tissue is enriched in the Ang II type 1 (AT1) receptor.23 We have shown recently
that Ang II stimulates sFlt-1 production by human trophoblast cells, placental villous
explants, and pregnant mice.25 These findings suggest that Ang II regulates sFlt-1 synthesis
and secretion by trophoblast cells of the placenta during pregnancy. Because Ang II levels
are not elevated in preeclampsia beyond that occurring in uncomplicated pregnancies,22,26
we must look for other factors to account for the additional synthesis and secretion of sFlt-1
associated with preeclampsia. Likely candidates are the angiotensin receptor–activating
autoantibodies present in women with preeclampsia.27 These autoantibodies interact with a
common epitope on the second extracellular loop of the AT1 angiotensin receptors.
Autoantibody-mediated activation of AT1 receptors on human trophoblast cells results in
increased production of reduced nicotinamide-adenine dinucleotide phosphate oxidase,
tissue factor, and plasminogen activator inhibitor-1. Activation of AT1 receptors by these
autoantibodies on various cell types provokes biological responses relevant to the
pathophysiology of preeclampsia.27–32 We report here that IgG from preeclamptic but not
normotensive pregnant individuals stimulates sFlt-1 synthesis and secretion by pregnant
mice, by human placental villous explants, and by cultured human trophoblasts. We show
that these autoantibodies are capable of inducing endothelial dysfunction via sFlt-1
induction. Notably we show that losartan and a 7-amino acid epitope peptide can prevent
AT1 receptor-activating autoantibody (AT1-AA)–induced sFlt-1 secretion and endothelial
dysfunction in vitro. Finally, we demonstrate that nuclear factor of activated T cells
(NFAT), a well known transcription factor activated by calcineurin signaling functioning
downstream of the AT1 receptor, may regulate sFlt-1 induction by AT1-AA at the
transcriptional level. Our findings suggest that angiotensin receptor agonistic autoantibodies
represent potentially important targets for diagnosis and therapeutic intervention in the
management of preeclampsia.
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Methods
Reagents
One-step RT-PCR kit, cell culture medium, antibiotics, and fetal bovine serum (FBS) were
purchased from Invitrogen. Ang II was from Sigma. Losartan was a generous gift from
Merck and Co, Inc. FK506 was purchased from Fujisawa Pharmaceuticals. Endothelial cell
culture medium EGM-2 was from Cambrex.
Patients
Patients who were admitted to Memorial Hermann Hospital were identified by the obstetric
faculty of the University of Texas Medical School at Houston. Patients were diagnosed with
severe preeclampsia based on the definition set by the National High Blood Pressure
Education Program Working Group report. The criteria include the presence of high blood
pressure of ≥160/110 mm Hg and the presence of protein in urine of ≥0.3 g in a 24-hour
period. These women had no previous history of hypertension. Other criteria included the
presence of persistent headache, visual disturbances, epigastric pain, or the HELLP
syndrome in women with blood pressure of ≥140/90 mm Hg. Normotensive pregnant
individuals were characterized by uncomplicated pregnancies with normal, term deliveries.
Characteristics of the patient population used for this study are provided in the Table. Blood
samples were centrifuged at 18 000g for 10 minutes, and the serum samples were stored at –
80°C. The research protocol, including the consent form, was approved by the institutional
committee for the protection of human subjects.
Preparation of the Immunoglobulin Fraction
The IgG fraction was isolated, as described previously,28 using GammaBind G Sepharose
(Amersham Biosciences). Typically, 200 μL of patient sera were applied to the column
matrix and eluted in 1.8 mL of buffer according to the manufacturer-recommended protocol.
This approach resulted in an ≈9-fold dilution of IgG from that originally present in patient
sera. Various dilutions of these samples, typically 1:10 or 1:20 dilution, were used for in
vitro assay using cultured cells or placental explants.
Synthetic Peptides
For the neutralization experiments, a synthetic peptide corresponding to a sequence present
on the second extracellular loop of the human AT1 receptor, AFHYESQ, was used. This
peptide was purchased from Baylor College of Medicine.
Introduction of Antibody Into Mice
C57BL/6J pregnant or nonpregnant mice (18 to 22 g; Harlan) were used in our study. All of
the animal studies were reviewed and approved by the animal welfare committee of the
University of Texas Houston Health Science Center. Mice were anesthetized with sodium
pentobarbital (50 mg/kg IP), and concentrated IgG purified from 200 μL of patient's serum
was introduced into 13-day pregnant mice or nonpregnant mice by orbital sinus injection.
Some animals also received losartan (0.24 mg) or a 7-amino acid peptide corresponding
with an epitope on the second extracellular loop of the AT1 receptor (1.5 mg). We collected
serum on gestation day 19 for measurement of the sFlt-1 concentration.
Human Placental Villous Explants Cultured With IgG
Human placental tissue was obtained from uncomplicated term pregnancies delivered by
elective cesarean section for breech presentation or a recurring indication in otherwise
uncomplicated pregnancies, as described previously.33,34 Informed consent was obtained
from the patients, and the study had the approval of the South Birmingham Ethical
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Committee. Five small fragments (15 to 20 mg wet weight) of placental villi were dissected
from the placenta, teased apart, and placed in 24-well plates. Placental villous explants were
cultured in phenol red-free DMEM (Sigma Ltd) supplemented with 100 μg/mL of
streptomycin, 100 U/mL of penicillin, and 0.2% BSA in 5% CO2 at 37°C. IgG purified from
normotensive and preeclamptic patients was added to the villous fragments at the indicated
concentrations and incubated for ≤72 hours at 37°C. For the inhibitor studies, losartan at 100
nM or a 7-amino acid peptide (AFHYESQ; 0.1 μmol/L) corresponding with an epitope on
the second extracellular loop of the AT1 receptor was added for 30 minutes before
stimulation with IgG. After 72 hours, the conditioned medium (CM) was collected and
stored at –20° for further analysis.
IgG Treatment and Collection of Conditioned Medium
For sFlt-1 induction, 1×105 human trophoblast cells HTR-8/SVneo35 were plated in 12-well
plates overnight. The next day, cells were changed to serum-free medium, treated with a
1:10 dilution of purified IgG, and incubated for an additional 3 or 4 days. For some
experiments, losartan (100 nM), FK506 (1 μmol/L), or the 7-amino acid epitope peptide
(AFHYESQ; 0.1 μmol/L) was added to culture medium 30 minutes before the addition of
IgG. After 3 or 4 days, cells and culture medium were collected and centrifuged at room
temperature for 15 minutes at 100g. Cell pellets were used for Western blot analysis.
Supernatants were termed conditioned medium (CM) and used for a variety of experiments.
The concentration of sFlt-1 in CM was determined by ELISA (see below). CM was also
used in the in vitro endothelial cell migration and capillary tube formation assays, as we
have described previously.25 For some experiments, sFlt-1 was depleted by incubation with
monoclonal anti-Flt antibody for 2 hours at 4°C before adding protein A overnight. The
following day, supernatants were collected after centrifugation to remove
immunoprecipitates and were used in endothelial cell tube formation and migration assays.
ELISA for sFlt-1
sFlt-1 levels in CM and in mouse serum were measured using a commercial kit (R and D
Systems).
Transfection of Small-Interfering RNA
HTR cells (1.0×105) were plated on 6-well plates overnight, and transfected with 3 μg of
small-interfering RNA (siRNA) specific for calcineurin catalytic subunit-α (CN) or with
nonspecific siRNA (Dharmacon) using RNAiFect transfection reagent (Qiagen). Non-
specific siRNA was used as a negative control. At 48 hours after transfection, cells were
cultured in serum-free medium and treated with IgG (1:10 dilution) from normotensive
women or from women with preeclampsia for 72 hours.25 Secreted sFlt-1 in cell culture
medium was measured by ELISA.
RNA Isolation and Semiquantitative RT-PCR
TRIzol reagent was used for the isolation of total RNA. RT-PCR was performed according
to the manufacturer's recommended protocol (Invitrogen). One microgram of RNA was used
per reaction, and the annealing temperature for PCR was 55°C. sFlt-1 primer sequences and
PCR conditions were as described14: sense primer, 5′-
TTTGCATAGCTTCCAATAAAGTTG, and antisense primer, 5′-
CATGACAGTCTAAAGTGGTGGAAC. β-Actin was used as an internal control, and
primer sequences were as described.25 RT-PCR products were revealed on 2% agarose gels
and quantified using Bio-Rad quantity-1 software. sFlt-1 mRNA expression was represented
by the ratio of sFlt-1 mRNA:β-actin mRNA.
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Luciferase Activity
Chinese Hamster Ovary cells (1×105 cells) containing stably integrated copies of a minigene
encoding the rat AT1 receptor and a 4×NFAT-driven luciferase construct were plated on 24-
well plates overnight. The next day cells were changed to serum-free medium and treated
with IgG (1:10 dilution) for 24 hours. Luciferase activity in cell lysates was measured using
a luciferase assay kit (Promega).
In Vitro Endothelial Cell Migration and Tube Formation
The in vitro cell migration assays were preformed as described.36 Briefly, human umbilical
vein endothelial cells (HUVECs; 2.5×104 per well) were prepared with 500 μL of EGM-2
basal medium and added to the inserts of the 24-well plates (BD Biosciences). CM was used
as a chemoattractant and added to the outside of the insert chamber. After 24 hours of
incubation at 37°C, migrated cells were stained with Quick-diff and counted. From 4 to 10
fields of cells were counted and the average recorded. This procedure was carried out in
triplicate for each sample of CM.
The endothelial cell in vitro tube formation assays were performed as described12 using 96-
well plates coated with growth factor–reduced Matrigel (BD Biosciences) and incubated at
37°C for 30 minutes. HUVECs, at a density of 2×104 cells per well, were incubated with
CM, plated on precoated 96-well plates, and incubated at 37°C in a CO2 incubator. Images
were taken after 4 hours of incubation, and tube lengths were measured using MetaMorph
software (Molecular Devices). Five to 10 fields were used to average the tube length.
Statistical Analysis
All of the values are expressed as the mean±SEM. Data were analyzed for statistical
significance using GraphPad Prism software (GraphPad Software). A value of P<0.05 was
considered significant.
Results
IgG From Women With Preeclampsia Stimulates sFlt-1 Secretion in Pregnant Mice
To evaluate the potential in vivo role of AT1-AA on sFlt-1 secretion in preeclampsia, we
introduced IgG from either preeclamptic or normotensive patients into pregnant and
nonpregnant mice. Because sFlt-1 secretion is normally induced late in pregnancy, we chose
to introduce IgG at gestation day 13. Mice were euthanized 5 days after injection, and serum
levels of sFlt-1 were determined by ELISA. The results show that circulating levels of sFlt-1
were significantly increased in the pregnant mice 5 days after injection of IgG from
preeclamptic women over that observed in the pregnant mice after injection of IgG from
normotensive pregnant women (Figure 1A). The concentration of sFlt-1 was very low in
nonpregnant mice and was not stimulated by injection with IgG from either normotensive or
preeclamptic women (Figure 1B), suggesting that placenta is the major source for excessive
secretion of sFlt-1 in antibody-injected mice. The antibody-mediated sFlt-1 induction in the
pregnant mice was prevented by the coinjection of losartan, an AT1 receptor antagonist, or
by a 7-amino acid peptide that corresponds with a site on the second extracellular loop of the
AT1 receptor that is recognized by autoantibodies from women with preeclampsia (Figure
1A). These findings indicate that IgG from preeclamptic patients induces sFlt-1 secretion in
pregnant mice through AT1 receptor activation.
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IgG From Preeclamptic Women Stimulates Excess sFlt-1 Secretion by Human Placental
Villous Explants via AT1 Receptor Activation
To determine whether AT1-AA stimulates sFlt-1 production by the placenta, human
placental villous explants were incubated with IgG purified from preeclamptic or
normotensive pregnant individuals. After 72 hours, the CM was collected, and the
concentration of sFlt-1 was determined. IgG purified from women with preeclampsia
induced an excessive secretion of sFlt-1 (Figure 2A). Similar to in vivo studies from
pregnant mice, the autoantibody-induced sFlt-1 secretion in pregnant mice was blocked by
losartan or the 7-amino acid epitope peptide. The autoantibody-induced stimulation of sFlt-1
secretion was prevented by the presence of losartan, an AT1 receptor antagonist, and by a 7-
amino acid peptide that corresponds to a site on the second extracellular loop of the AT1
receptor that is recognized by autoantibodies from women with preeclampsia. These
findings indicate that IgG from women with preeclampsia is capable of inducing sFlt-1
secretion via AT1 receptor activation in human placentas.
To determine whether Ang II and AT1-AA can function additively to stimulate sFlt-1
secretion, we incubated human placental villous explants with limiting concentrations of
Ang II or AT1-AA individually or in combination. After 72 hours, the concentration of
sFlt-1 in the medium was determined. sFlt-1 secretion was significantly induced by Ang II
or AT1-AA alone (Figure 2B). However, the combination of Ang II and AT1-AA resulted in
a significantly higher stimulation than either alone (Figure 2B). These findings imply that
the excessive production of sFlt-1 in women with preeclampsia may be because of the
additional autoantibody-mediated activation of AT1 receptors in their placentas.
IgG From Women With Preeclampsia Stimulates sFlt-1 Secretion by Human Trophoblast
Cells via AT1 Receptor Activation
We have reported recently that Ang II stimulates sFt-1 synthesis and secretion from human
trophoblast cells.25 Thus, it is likely that trophoblast cells are the source of the autoantibody-
induced sFlt-1 production from placental villous explants.14,37,38 To test this possibility, we
incubated immortalized human trophoblasts cells HTR-8/SVneo with IgG purified from
preeclamptic or normotensive pregnant individuals and determined the concentration of
sFlt-1 in the CM after 4 days. IgG from preeclamptic individuals induced a significant
increase in sFlt-1 secretion, whereas IgG from normotensive pregnant women did not
(Figure 3A). The autoantibody-mediated induction of sFlt-1 secretion in the human
trophoblast cells was inhibited by the presence of losartan or the 7-amino acid epitope
peptide (Figure 3A). These results provide in vitro evidence that autoantibodies associated
with women with preeclampsia are capable of activating AT1 receptors on human
trophoblast cells, resulting in increased sFlt-1 secretion.
As with human placental villous explants, we found that Ang II and AT1-AA can function
additively to stimulate sFlt-1 secretion by cultured human trophoblast cells (Figure 3B).
Specifically, we found that sFlt-1 secretion was significantly induced by Ang II or AT1-AA
alone (Figure 3B). The combination of Ang II and AT1-AA resulted in a significantly higher
stimulation than either alone (Figure 3B). These findings imply that the excessive secretion
of sFlt-1 in preeclampsia may be because of additional AT1 receptor activation by AT1-AA
present in these women.
Calcineurin/NFAT Signaling Functions Downstream of the AT1 Receptor and Is Required
for Autoantibody-Induced sFlt-1 Production by Human Trophoblast Cells
Calcineurin signaling pathways play important roles in multiple pathological conditions,
including hypertension and cardiac hypertrophy.39 – 41 Previous studies have shown that
calcium calmodulin–dependent calcineurin signaling functions downstream of the AT1
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receptor in response to AT1-AA–mediated plasminogen activator inhibitor-1 induction in
human trophoblast cells.35 To determine whether calcineurin signaling is associated with
autoantibody-mediated stimulation of sFlt-1 secretion by human trophoblast cells, we
initially used FK506, a well-known specific inhibitor of calcineurin activity. The results
(Figure 4A) show that the increased sFlt-1 secretion mediated by IgG from women with
preeclampsia was blocked by the presence of FK506. FK506 had no effect on sFlt-1
secretion in the cells treated with IgG from normotensive pregnant women (Figure 4A). The
involvement of calcineurin signaling was confirmed using siRNA specific to mRNA
encoding the calcineurin catalytic subunit α.25 As with FK506, we found that autoantibody-
induced stimulation of sFlt-1 secretion was significantly inhibited by the presence of
calcineurin-specific siRNA (CN siRNA) but not by the presence of nonspecific siRNA
(Figure 4B). Taken together, these findings show that calcineurin signaling functions
downstream of autoantibody-induced AT1 receptor activation to stimulate sFlt-1 secretion
by human trophoblast cells.
Realizing that the abundance of sFlt-1 mRNA is elevated in placentas from women with
preeclampsia,12 we wanted to know whether AT1-AA-induced sFlt-1 secretion in human
trophoblast cells was accompanied by an increase in sFlt-1 mRNA. To address this issue,
trophoblast cells were treated in a variety of ways, and the abundance of sFlt-1 mRNA was
assessed using RT-PCR. The results (Figure 5A and 5B) show that sFlt-1 mRNA abundance
was significantly induced by IgG from women with preeclampsia but not IgG from
normotensive pregnant women and that the induction was inhibited by losartan or the 7-
amino acid epitope peptide. In addition, preincubation with FK506 blocked the antibody-
mediated induction of sFlt-1 mRNA (Figure 5A and 5B), suggesting that sFlt-1 mRNA
upregulation by AT1-AA requires calcineurin signaling.
Calcineurin plays a critical role in a number of signal transduction pathways by catalyzing
the dephosphorylation of the transcription factor, NFAT, thereby allowing the latter to enter
the nucleus and participate in the transcriptional activation of target genes. Thus, we
hypothesize that autoantibody-mediated stimulation of sFlt-1 mRNA levels through AT1
receptor activation is a transcriptional response associated with the calcineurin-mediated
activation of NFAT. To assess this possibility, we measured the activity of an NFAT-
luciferase reporter construct in Chinese hamster ovary cells treated with IgG from
normotensive pregnant women or from women with preeclampsia in the presence or absence
of losartan, the 7-amino acid epitope peptide, or FK506. IgG from preeclamptic patients
stimulated the activity of the NFAT-luciferase reporter gene, whereas IgG from
normotensive pregnant women did not (Figure 5C). This induction was blocked by the
presence of losartan, the 7-amino acid epitope peptide or FK506 (Figure 5C). These findings
suggest that the AT1-AA–mediated induction of sFlt-1 mRNA results from an NFAT-
mediated transcriptional enhancement of the Flt-1 gene.
Autoantibody-Induced sFlt-1 Inhibits Endothelial Cell Function
Placental-derived sFlt-1 is believed to contribute to endothelial dysfunction in
preeclampsia.12,42 To determine whether the autoantibody-induced sFlt-1 produced by
cultured human trophoblast cells is biologically active, we incubated human trophoblast
cells with IgG from preeclamptic or normotensive pregnant individuals and tested CM for its
impact on endothelial cell migration and tube formation. CM from human trophoblast cells
treated with IgG from women with preeclampsia showed a 50% reduction in endothelial cell
(HUVEC) migration (Figure 6A) and tube formation (Figure 6B and 6C) when compared
with CM from trophoblast cells treated with IgG from normotensive pregnant women.
Importantly, removal of sFlt-1 using anti–sFlt-1 antibody from preeclamptic IgG-treated
trophoblast CM eliminated the antimigratory properties (Figure 6A) and reduced the in vitro
antiangiogenic activity (Figure 6B and 6C). These results indicate that sFlt-1 accounted for
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the reduction in angiogenic activity seen in CM from trophoblast cells treated with IgG from
preeclamptic individuals. The inhibitory properties of the CM from preeclamptic IgG-treated
trophoblast cells were prevented by the presence of losartan or FK506, indicating that
blockade of AT1 receptor activation or downstream calcineurin signaling prevented the
autoantibody-mediated induction of sFlt-1 (Figure 6). The presence of the 7-amino acid
epitope peptide also prevented the appearance of autoantibody-induced antiendothelial
properties of CM. Taken together, these studies show that autoantibody-mediated AT1
receptor activation results in the increased production of trophoblast-derived sFlt-1 that can
inhibit endothelial cell migration and tube formation resulting in autoantibody-induced
endothelial dysfunction.
Discussion
We report here that IgG from women with preeclampsia stimulates sFlt-1 synthesis and
secretion by pregnant mice, human placental villous explants, and human trophoblast cells
through AT1 receptor activation and that the increased production of sFlt-1 results in the
inhibition of endothelial cell migration and capillary tube formation. Notably, losartan or an
antibody-blocking epitope peptide prevented the excessive sFlt-1 secretion, thereby
highlighting therapeutic possibilities for the treatment of preeclampsia. In addition, we have
shown that NFAT, a transcription factor and a well-known calcineurin substrate, is required
for antibody-mediated transcriptional enhancement of the FLT-1 gene. In summary, our
studies indicate that autoantibodies functioning as Ang II are capable of activating AT1
receptors and contribute to excess sFlt-1 secretion in preeclampsia.
The level of sFlt-1 in the maternal circulation increases significantly during the third
trimester.16,43,44 We have shown recently that Ang II stimulates increased production of
sFlt-1 by human placental villous explants, human trophoblast cells, and in pregnant mice.25
We speculate that the increase in circulating sFlt-1 that occurs during the third trimester of a
normal pregnancy is because of the increase in circulating Ang II that occurs at this
time.20–22,45 Preeclampsia is characterized by an earlier and more extensive increase in the
concentration of circulating sFlt-1.16–18 Factors accounting for the precocious and excessive
accumulation of sFlt-1 associated with preeclampsia have not been identified previously.
Ang II levels are not elevated in preeclampsia over that occurring in a normal
pregnancy,20,22,26,45,46 and, therefore, other factors may contribute to the elevated levels of
sFlt-1 observed in women with preeclampsia. We hypothesize that AT1-AA present in
women with preeclampsia contributes to the increased production of sFlt-1 observed in these
women. These autoantibodies are detected at as early as 18 to 20 weeks of gestation in
women with impaired placental development,47 thereby placing their appearance within a
time-frame congruent with subsequent increases in circulating sFlt-1.16 Here, we showed
that IgG from women with preeclampsia activates AT1 receptors and thereby stimulates
increased sFlt-1 secretion from human placental explants and cultured human trophoblast
cells. We also showed that Ang II and AT1-AA can function additively to induce increased
sFlt-1 secretion through additional AT1 receptor activation. We suggest that Ang II is a key
regulator of sFlt-1 synthesis and secretion during normal pregnancy25 and that the excessive
accumulation of sFlt-1 observed in women with preeclampsia is because of additional
activation of AT1 receptors mediated by AT1-AA.
The following lines of evidence indicate that autoantibody-induced sFlt-1 secretion results
from transcriptional activation of the FLT-1 gene. First, we have shown here that
autoantibody-induced sFlt-1 secretion is accompanied by a corresponding increase in sFlt-1
mRNA abundance. Second, a transcriptional control mechanism is suggested by our finding
that antibody-mediated AT1 receptor activation is accompanied by downstream activation of
the calcineurin/NFAT signaling pathway. Calcineurin is a calcium/calmodulin-dependent
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phosphatase that dephosphorylates multiple residues within the regulatory domain of the
transcription factor NFAT, leading to its nuclear translocation and the activation of target
genes. Additional evidence for the importance of autoantibody-induced NFAT activation
comes from experiments using Chinese hamster ovary cells stably transformed with an
NFAT-luciferase reporter gene. We found that the NFAT-luciferase reporter gene was
activated by IgG from women with preeclampsia and that the activation was blocked by the
calcineurin inhibitor FK506. Finally, a role for NFAT in the transcriptional regulation of the
FLT-1 gene is consistent with the presence of 4 consensus NFAT binding sites in the 5′
flanking region of the gene within 550 bp of the transcription start site (GenBank accession
No. D64016). Overall, our findings suggest that NFAT, functioning downstream of
calcineurin, may directly regulate FLT-1 transcriptional activation after autoantibody-
mediated AT1 receptor activation.
In addition to AT1-AA, other factors may contribute to the increased sFlt-1 secretion
associated with preeclampsia. Preeclampsia is often associated with poorly developed
placentas characterized by shallow trophoblast invasion, deficient spiral artery remodeling,
and reduced perfusion. These placental abnormalities result in a hypoxic environment for the
placenta that is believed to contribute to increased sFlt-1 production in preeclampsia.14,48–50
It has been suggested that hypoxia-induced upregulation of sFlt-1 expression is through the
presence of hypoxia-inducible factor-1α response elements in the sFLT-1 promoter region.51
Reduced oxygen tension is also associated with increased production of placental cytokines,
including tumor necrosis factor-α, which is elevated in the maternal circulation of women
with preeclampsia.42,52 Recent studies show that tumor necrosis factor-α, in a concentration-
dependent manner, stimulates the release of sFlt-1 from placental villous explants.42
Complement activation, especially C5a, is associated with increased sFlt-1 production.53
Negative regulators of sFlt-1 production have also been identified. The carbon monoxide
produced by the heme oxygenase reaction serves as a negative regulator of sFlt-1
production.54 Thus, multiple factors influence sFlt-1 production by the placenta. Stepan et
al55 have recently examined the relationship between AT1-AA and elevated sFlt-1 in
pregnant women. They found that most of the preeclamptic patients were characterized by
high sFlt-1 levels and the presence of AT1-AA. However, discordance between AT1-AA
and sFlt-1 was observed in a population of patients characterized by reduced uterine
perfusion and no other pregnancy complications. In these cases, AT1-AA was frequently
present, whereas sFlt-1 was not usually elevated. They also identified an occasional
preeclamptic patient with elevated sFlt-1 who lacked AT1-AA. Thus, in addition to AT1-
AA, other factors influence sFlt-1 production and may account for those cases identified by
Stepan et al55 in which there is discordance between sFlt-1 and AT1-AA in pregnant
women.
Important recent work by Walther et al47 shows that AT-AA can be detected before 20
weeks in women with impaired uterine perfusion detected by Doppler sonography. The fact
that AT1-AA can be detected many weeks before the symptoms of preeclampsia has
significant implications regarding early diagnosis and therapeutic intervention. If maternal
circulating AT1-AA contributes to the pathophysiology of preeclampsia, the removal of
these autoantibodies from women with preeclampsia may provide therapeutic benefit.
Another possible therapeutic approach is to block the action of the autoantibody. AT1-AAs
typically recognize a 7-amino acid sequence present on the second extracellular loop of the
AT1 receptor. Available evidence indicates that a 7-amino acid peptide, corresponding with
this epitope, blocks antibody-induced stimulation of the AT1 receptor.27,28 Our current
studies show that this 7-amino acid peptide can neutralize AT1-AA and thereby prevent
autoantibody-induced sFlt-1 production in placental explants and cultured trophoblast cells.
Thus, the use of epitope peptide therapy to block the action of angiotensin receptor–
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activating autoantibodies has the potential of being a safe and effective treatment of
preeclampsia.
Perspectives
In 1999, Wallukat et al27 reported their remarkable findings that sera from women with
preeclampsia contain autoantibodies that react with the AT1 receptor in a stimulatory
fashion. In recent years, these important findings have been extended in numerous ways
showing that these autoantibodies activate AT1 receptors on cardiac myocytes, trophoblast
cells, endothelial cells, mesangial cells, vascular smooth muscle cells, and Chinese hamster
ovary cells.56,57 Here we reported that these autoantibodies stimulate increased production
of sFlt-1 by human trophoblast cells, human villous explants, and in pregnant mice and in
this way may contribute to the production of a major soluble factor released from the
placenta that contributes to the maternal syndrome. Altogether, the studies show that the
AT1-AAs activate AT1 receptors on a variety of cell types and provoke biological responses
that are relevant to the pathophysiology of preeclampsia. These findings provide a new way
of thinking about the abnormalities associated with preeclampsia and raise the possibility
that preeclampsia may be an autoimmune disease. Thus, removing AT1-AA or inhibiting
AT1 receptor activation by 7-amino acid antibody-blocking epitope peptide may be a
potential safe and effective therapeutic treatment for preeclampsia.
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Figure 1.
IgG from women with preeclampsia stimulates sFlt-1 secretion in pregnant mice. IgG from
normotensive or preeclamptic pregnant women was introduced by retro-orbital injection into
pregnant (day 13) (A) or nonpregnant mice (B). A, Pregnant mice were injected with IgG
from women with preeclampsia in the presence or absence of losartan or the 7-amino acid
epitope peptide (7-AA). Mice were euthanized 5 days after injection, and the serum
concentrations of sFlt-1 were determined by ELISA. *P<0.05 vs pregnant mice injected
with normotensive IgG. **P<0.05 vs pregnant mice injected with preeclampsia IgG alone.
n=5 to 8.
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Figure 2.
IgG from women with preeclampsia stimulates sFlt-1 secretion in human placental villous
explants through AT1 receptor activation. A, Placental villous explants were incubated in
serum-free medium containing 0.2% BSA and treated with IgG (1:10 dilution) for 72 hours
with or without losartan (L) or 7-amino acid epitope peptide (7-AA) corresponding to a
sequence present on the second extracellular loop of the AT1 receptor that is recognized by
AT1-AA (0.1 μmol/L). The CM was collected, and the amount of secreted sFlt-1 was
determined by ELISA. B, Additive effects of Ang II and AT1-AA resulted in higher
induction of sFlt-1. Human placental villous explants were treated with IgG from
preeclamptic patients (1:20) or Ang II (10 nM), alone or in combination, for 72 hours. The
concentration of sFlt-1 present in the CM was determined by ELISA specific for human
sFlt-1. Data are expressed as mean±SEM. *P<0.05 relative to control; **P<0.05 relative to
Ang II or IgG-treated samples.
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Figure 3.
IgG from women with preeclampsia stimulates secretion of sFlt-1 via AT1 receptor
activation in human trophoblast cells. A, Immortalized human trophoblast cells (HTR-8/
SVneo) were treated with IgG (1:10 dilution) for 4 days in the presence or absence of
losartan or a 7-amino acid peptide (7-AA; 0.1 μmol/L). The concentration of sFlt-1 in CM
was determined by ELISA. Each sample was analyzed in triplicate, and the resulting value
for each patient sample is shown. The horizontal line represents the mean for the data points
in each group. B, HTR-8/SVneo cells were treated with IgG from preeclamptic patients
(1:20) or Ang II (10 nmol/L), alone or in combination, for 72 hours. The concentration of
sFlt-1 present in the CM was determined by ELISA specific for human sFlt-1. Data are
expressed as mean±SEM. *P<0.05 relative to control; **P<0.05 relative to Ang II or IgG-
treated samples.
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Figure 4.
Calcineurin signaling is required for AT1-AA–mediated sFlt-1 induction. A, HTR-8/SVneo
cells were incubated with IgG from normotensive pregnant women (n=7) or from women
with preeclampsia (n=14) for 4 days in the presence or absence of FK506 (1 μmol/L). The
concentration of sFlt-1 present in the culture medium was determined by ELISA specific for
human sFlt-1. Each sample was analyzed in triplicate. Data are expressed as mean±SEM.
*P<0.01 vs normotensive IgG treatment; **P<0.05 vs preeclampsia IgG treatment. B,
HTR-8/SV-neo cells were transfected with nonspecific siRNA (NS siRNA) and specific
siRNA for calcineurin catalytic subunit α mRNA (CN siRNA). Forty-eight hours after
transfection, the cellular level of calcineurin catalytic subunit α (CN) was evaluated by
Western blot analysis. A typical result is shown in the inset. The transfected cells (48 hours
posttransfection) were treated with IgG for 4 days, and the concentration of sFlt-1 in the CM
was determined by ELISA. Each sample was analyzed in triplicate. Data are expressed as
mean±SEM. *P<0.01 vs control; **P<0.05 vs preeclampsia IgG treatment.
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Figure 5.
NFAT functions downstream of calcineurin to regulate AT1-AA–mediated sFlt-1 induction
at transcriptional level. A, Total RNA was isolated from HTR-8/SVneo cells treated with
IgG from normotensive pregnant women (NT) and women with preeclampsia (PE).
Semiquantitative RT-PCR was used to quantify sFlt-1 mRNA from the treated cells. RT-
PCR products were visualized by electrophoresis on 2% agarose gels, and β-actin was used
to normalize the sFlt-1 mRNA abundance. B, The ratio of sFlt-1 mRNA:β-actin was
obtained by using densitometric analysis of multiple agarose gels. Data are expressed as
mean±SEM. *P<0.05 vs control; **P<0.05 vs preeclamptic IgG treatment. C, Cells stably
transformed with an NFAT (4 copy)-driven luciferase (Luc) reporter gene were cultured in
serum-free medium and treated with IgG from normotensive pregnant women or IgG from
women with preeclampsia for 4 days in the presence or absence of losartan, 7-amino acid
epitope peptide (7-AA; 0.1 μmol/L), or FK506 (1 μmol/L). Luciferase activity was
determined in cell lysates. Each sample was analyzed in triplicate. Data are expressed as
mean±SEM. *P<0.01 vs normotensive IgG treatment; **P<0.05 vs preeclampsia IgG
treatment.
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Figure 6.
Autoantibody-induced sFlt-1 inhibits endothelial cell functions. CM from HTR-8/SVneo
cells treated with IgG from normotensive or preeclamptic pregnant women was added to
cultured endothelial cells, and the effect on cell migration (A) and tube formation (B and C)
were determined. In some cases, HTR-8/SVneo cells were treated with the 7-amino acid
epitope peptide (7-AA; 0.1 μmol/L) or losartan (1 μmol/L) in addition to IgG. A, For cell
migration, HUVECs were grown in serum-free medium in a cell migration chamber, and
CM was used as chemoattractant. Migrated cells were counted after 24 hours of incubation.
Each sample was counted in triplicate and repeated 3 times. Data are expressed as mean
±SEM. *P<0.05 preeclampsia vs normotensive IgG; **P<0.05 vs preeclampsia IgG
treatment alone. Inset, CM from IgG treated HTR-8 SV40/neo cells was incubated with
anti–Flt-1 antibody, and the immunoprecipitated (IP) protein was analyzed by Western blot
analysis (WB) using specific Flt-1 antibody. B, For tube formation, HUVEC cells were
plated on growth factor–reduced Matrigel with different CM and incubated for 4 hours at
37°C. Images were taken by light microscopy and are representative photomicrographs of
HUVECs plated on growth factor–reduced Matrigel and stimulated with different CMs. C,
Tube circumferences were measured using MetaMorph software. Four to 10 fields were
used to obtain average tube length. Data are expressed as mean±SEM. * P<0.05
preeclampsia vs normotensive IgG; **P<0.05 vs preeclampsia IgG treatment.
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Table
Clinical Characteristics of the Patients Involved in This Study
Features of Patients Normal (n=7) Severe Preeclampsia
Maternal age, mean±SEM, y 32.6±0.8 31.5±0.9
Gestational age, mean±SEM, wk 38.7±0.5 32.7±0.9
Primiparous, % 26 85
Systolic blood pressure, mm Hg <140 164±7.5
Diastolic blood pressure, mm Hg <90 105±4.5
sFlt-1, ng/mL <0.3 6.7±1.5
AT1-AA induced NFAT-luc activity 1.1±0.5 6.4±1.4*
sFlt-1- and AT1-AA–induced NFAT-luciferase activity were measured as described in the Methods section. Data are expressed as mean±SEM.
*
P<0.05 for preeclampsia vs normotensive IgG.
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